Compare ANNX & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | SBGI |
|---|---|---|
| Founded | 2011 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 1.0B |
| IPO Year | 2020 | 2023 |
| Metric | ANNX | SBGI |
|---|---|---|
| Price | $5.36 | $13.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $16.50 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.1M | 397.8K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | N/A | ★ $3,169,000,000.00 |
| Revenue This Year | N/A | $12.37 |
| Revenue Next Year | $16,320.74 | N/A |
| P/E Ratio | ★ N/A | $51.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.85 | $11.89 |
| 52 Week High | $7.18 | $17.88 |
| Indicator | ANNX | SBGI |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 42.52 |
| Support Level | $4.80 | $13.02 |
| Resistance Level | $5.61 | $15.49 |
| Average True Range (ATR) | 0.28 | 0.49 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 55.96 | 31.14 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.